ライフサイエンスコーパス: ACHD

1 ACHD diagnoses were subclassified as isolated aortic val

2 ACHD experts can provide expertise in the management of

3 ACHD patients continue to be afflicted by increased mort

4 ACHD-exposed individuals with <=2 cardiovascular risk fa

5 Disease Patient-Reported Outcome Version 1 (ACHD PRO V.1) and hospital admission within the precedin

6 CHD and 38,557 non-ACHD patients listed, 237 ACHD and 6,377 non-ACHD patients died or were delisted d

7 patients initially listed as status 1A (24% ACHD vs. 17% non-ACHD after 180 days; p < 0.001).

8 Among 1,290 ACHD and 38,557 non-ACHD patients listed, 237 ACHD and 6

9 Overall, 467 ACHD participants were enrolled (82 dextro-transposition

10 A total of 163 (56%) ACHD patients in the new era versus 150 (62%) in the pri

11 vide a quality of care assessment tool for 6 ACHD conditions.

12 METHODS AND Of 25 790 ACHD patients in an international multicenter registry,

13 e for predicting in-hospital mortality after ACHD surgery.

14 support a model of specialized care for all ACHD patients.

15 ts (ages 18-30 years) from 14 North American ACHD centers.

16 uring the first 300 days after listing among ACHD patients without altering early posttransplant outc

17 ransplant mortality and length of stay among ACHD patients in both eras and between ACHD and non-ACHD

18 ary care physicians,adult cardiologists, and ACHD specialists to provide optimal care for these women

19 ferral rates to specialized ACHD centers and ACHD patient mortality rates between 1990 and 2005 in th

20 ically significant reductions in overall and ACHD mortality in the men, but not in the women.

21 These findings might assist ACHD programs in developing strategies to identify and r

22 among ACHD patients in both eras and between ACHD and non-ACHD patients in the new era.

23 lysis indicated a strong association between ACHD PRO V.1 domains and relevant clinical variables.

24 here were no significant differences between ACHD and non-ACHD patients listed as status 1B or 2.

25 ant difference in peak VO2 was found between ACHD and heart failure patients of corresponding NYHA cl

26 We also examined the relationship between ACHD PRO V.1 domain scores and domain-relevant clinical

27 ts and guidance on ASCVD prevention for both ACHD specialists and non-ACHD cardiologists are provided

28 We included 37 278 patients with adult CHD (ACHD) and 412 799 controls.

29 of Transplant Recipients (SRTR) we compared ACHD patients listed for the first-time for heart transp

30 es were observed among patients with complex ACHD, Fontan physiology, and Eisenmenger syndrome.

31 ified 2006 individuals with lower-complexity ACHD and 497 983 unexposed individuals in the UK Biobank

32 to select individuals with lower-complexity ACHD and individuals without ACHD for comparison among >

33 Individuals with lower-complexity ACHD had a higher burden of adverse cardiovascular event

34 ular events associated with lower-complexity ACHD that is unmeasured by conventional risk factors.

35 ise testing was performed in 335 consecutive ACHD patients (age, 33+/-13 years), 40 non-congenital he

36 The cohort included 3392 consecutive ACHD patients under long-term follow-up at a tertiary AC

37 f noncardiac causes of death in contemporary ACHD patients.

38 rformance in adult congenital heart disease (ACHD) are limited to nondisease-specific metrics.

39 dult patients with congenital heart disease (ACHD) are still afflicted by premature death.

40 barriers to adult congenital heart disease (ACHD) care, as perceived by pediatric cardiologists (PCs

41 Data from Adult Congenital Heart Disease (ACHD) centres that follow up Tetralogy of Fallot patient

42 atients with adult congenital heart disease (ACHD) die after the age of 40 years, and heart failure (

43 Adults with congenital heart disease (ACHD) experience worse waitlist outcomes and higher earl

44 The adult with congenital heart disease (ACHD) faces medical, surgical, and psychosocial issues t

45 ns for adults with congenital heart disease (ACHD) in the U.S.

46 atients with adult congenital heart disease (ACHD) is rapidly increasing.

47 uces atherosclerotic coronary heart disease (ACHD) mortality, ACHD mortality combined with a new conf

48 Adult congenital heart disease (ACHD) patients have ongoing morbidity and reduced long-t

49 Adult congenital heart disease (ACHD) patients represent a growing population with incre

50 mortality in adult congenital heart disease (ACHD) patients.

51 zed care for adult congenital heart disease (ACHD) patients.

52 anagement of adult congenital heart disease (ACHD) patients.

53 atients with adult congenital heart disease (ACHD) report limitations in exercise capacity, we hypoth

54 Adults with congenital heart disease (ACHD) undergo repeated cardiac interventions, develop ca

55 research in adult congenital heart disease (ACHD) was convened in September 2004 under the sponsorsh

56 majority of adult congenital heart disease (ACHD), the long-term risks of adverse cardiovascular eve

57 atients with adult congenital heart disease (ACHD)-by definition-have underlying cardiovascular disea

58 ity in adults with congenital heart disease (ACHD).

59 c surgery in adult congenital heart disease (ACHD).

60 rajectory of adult congenital heart disease (ACHD).

61 r many adults with congenital heart disease (ACHD).

62 among adults with congenital heart disease (ACHD).

63 with ACHD treated with SGLT2i in 4 European ACHD centers were included in this retrospective study.

64 rt of patients operated in a second European ACHD center.

65 arallel, a significant reduction in expected ACHD patient mortality was observed after year 2000 (rat

66 for 12 measured cardiovascular risk factors, ACHD remained strongly associated with the primary end p

67 The number of hospital admissions for ACHD in the U.S. more than doubled between 1998 and 2005

68 of guidelines endorsing specialized care for ACHD patients.

69 ical status is disproportionately common for ACHD patients listed as status 1A.

70 mote quality measurement and improvement for ACHD patients.

71 g for clinical worsening was more likely for ACHD patients initially listed as status 1A (24% ACHD vs

72 transplant listing, impact the outcomes for ACHD patients listed for heart transplantation.

73 d in development of the first set of QIs for ACHD care based on published data, guidelines, and a mod

74 ore developed and validated specifically for ACHD patients undergoing cardiac surgery.

75 Of 12 723 listed patients, 535 had ACHD (293 in the new era) and 12 188 did not (6258 in th

76 Poor exercise capacity identifies ACHD patients at risk for hospitalization or death.

77 suggested natriuretic peptides may identify ACHD patients with adverse outcome.

78 e 2014 Consensus Statement on Arrhythmias in ACHD patients and the 2015 European Society of Cardiolog

79 may have demonstrated a possible benefit in ACHD prognosis from effective lipid intervention in wome

80 Exercise capacity is depressed in ACHD patients (even in allegedly asymptomatic patients)

81 he-art overview of acquired heart disease in ACHD patients and guidance on ASCVD prevention for both

82 and management of acquired heart disease in ACHD patients is currently not available, as this topic

83 tion factor 15 with cardiovascular events in ACHD.

84 k v2) measures of neurocognitive function in ACHD patients (ages 18-30 years) from 14 North American

85 ree three-dimensional whole-heart imaging in ACHD, with shorter, more predictable acquisition time an

86 fied recommendations for ICD implantation in ACHD patients for the first time.

87 asoning when deciding on ICD implantation in ACHD patients, therefore, remains vital.

88 antly associated with all-cause mortality in ACHD independent of congenital heart disease diagnosis,

89 nce of anemia and its relation to outcome in ACHD remain unknown.

90 s a direct and surrogate clinical outcome in ACHD.

91 oxygen consumption (peak VO2) was reduced in ACHD patients compared with healthy subjects of similar

92 lity of these ICD recommendations for SCD in ACHD patients.

93 NHLBI on the current state of the science in ACHD and barriers to optimal clinical care, and to make

94 using input from physicians specializing in ACHD to assess the symptoms patients associate with dise

95 t disease be guided by clinicians trained in ACHD.

96 Anemia is not uncommon in ACHD patients attending tertiary services and is associa

97 A risk score, developed and validated in ACHD, can be helpful to optimize risk assessment.

98 g due to clinical worsening within 1 year in ACHD included: estimated glomerular filtration rate <60

99 the QIs to a 9-member panel of international ACHD experts.

100 A lower ACHD PRO V.1 summary score is associated with a history

101 rveillance of patients with mild to moderate ACHD and further investigation into management and mecha

102 tic coronary heart disease (ACHD) mortality, ACHD mortality combined with a new confirmed nonfatal my

103 ly listed as status 1A (24% ACHD vs. 17% non-ACHD after 180 days; p < 0.001).

104 ACHD patients listed, 237 ACHD and 6,377 non-ACHD patients died or were delisted due to clinical wors

105 Among 1,290 ACHD and 38,557 non-ACHD patients listed, 237 ACHD and 6,377 non-ACHD patien

106 prevention for both ACHD specialists and non-ACHD cardiologists are provided.

107 tients in both eras and between ACHD and non-ACHD patients in the new era.

108 significant differences between ACHD and non-ACHD patients listed as status 1B or 2.

109 known how current criteria, derived from non-ACHD populations, used to determine priority at the time

110 tigate outcomes of ACHD in comparison to non-ACHD patients while listed for heart transplantation.

111 rly posttransplant mortality compared to non-ACHD patients.

112 changing the gap in outcomes compared to non-ACHD patients.

113 Overall, 830 noncyanotic ACHD patients (age 36.5 +/- 15.0 years, 49.6% male) fulf

114 ta were collected on consecutive noncyanotic ACHD patients attending our tertiary center between 2001

115 the association between responses to a novel ACHD-specific PRO metric and both clinical variables and

116 akes into account the distinctive aspects of ACHD patients may help better care for this growing popu

117 should be part of the routine assessment of ACHD patients for risk stratification and treatment when

118 ould be managed by or with the assistance of ACHD cardiologists.

119 In addition, the complex background of ACHD often curbs appropriate preventive strategies by ge

120 g Group reviewed data on the epidemiology of ACHD, long-term outcomes of complex cardiovascular malfo

121 Working groups of ACHD experts reviewed published data and United States,

122 or the ESC guidelines for the management of ACHD.

123 The number of ACHD hospitalizations increased 101.9% from 35,992 +/- 2

124 of this study was to investigate outcomes of ACHD in comparison to non-ACHD patients while listed for

125 There is a growing population of ACHD as the result of advances in pediatric care and dia

126 onger-term implications for the provision of ACHD care.

127 ent of the most common clinical scenarios of ACHD patients presenting to the ED.

128 relevant to patients across the spectrum of ACHD and remarkable homogeneity of patient experience, s

129 ymptoms from patients across the spectrum of ACHD and to examine whether reported symptoms were simil

130 symptoms were similar across the spectrum of ACHD as a foundation for creating a patient-reported out

131 iuretic peptide (BNP) across the spectrum of ACHD in a large contemporary cohort.

132 e emerging data of the effect of COVID-19 on ACHD patients, but many aspects, especially risk stratif

133 m to discuss the broad impact of COVID-19 on ACHD patients, focusing specifically on pathophysiology,

134 to examine the impact of specialized care on ACHD patient mortality.

135 A lack of qualified ACHD care providers was noted by 76% of PCs.

136 Medical Specialties has recently recognized ACHD as a subspecialty of cardiovascular disease to trea

137 ting neurocognitive assessments into routine ACHD care.

138 ohort and case-control analyses, specialized ACHD care was independently associated with reduced mort

139 The association between specialized ACHD care and all-cause mortality was assessed in both c

140 Moreover, referral to specialized ACHD care was independently associated with a significan

141 We examined referral rates to specialized ACHD centers and ACHD patient mortality rates between 19

142 ificant increase in referrals to specialized ACHD centers followed the introduction of the clinical g

143 nt increase in referral rates to specialized ACHD centers in 1997 (rate ratio, +7.4%; 95% confidence

144 ents under long-term follow-up at a tertiary ACHD centre between 2006 and 2019.

145 ortance of specialized follow-up at tertiary ACHD centers has been highlighted.

146 In addition, the ACHD PRO V.1 domains show good content validity by compa

147 These data support the use of the ACHD PRO V.1 as a direct and surrogate clinical outcome

148 Of the ACHD-exposed group, 59% were male, 51% were current or f

149 Because many of these ACHD patients are lost to follow-up in adulthood, pregna

150 were less likely to identify this barrier to ACHD care (p = 0.002).

151 The most perceived barrier to ACHD care was emotional attachment of parents and patien

152 at prompt referral and perceived barriers to ACHD care were identified.

153 ondents in the United States provide care to ACHD patients.

154 patient characteristic prompting referral to ACHD care was adult comorbidities (83%).

155 s redesigned giving unique listing status to ACHD patients.

156 tunity to establish or reestablish care with ACHD specialists and to reestablish continuing long-term

157 In this prospective study, participants with ACHD undergoing cardiac MRI between July 2020 and March

158 Altogether, 1937 patients with ACHD (5.2%) and 6690 controls (1.6%) died, a death rate

159 Patients with ACHD aged >=40 years between 2000 and 2010 were identifi

160 In patients with ACHD aged >=40 years, incident HFH was associated with h

161 At least 75% of patients with ACHD alive at 18 years of age lived past middle age and

162 ventional risk marker model in patients with ACHD and can reliably exclude the risk of death and hear

163 Many patients with ACHD are also afflicted with residual haemodynamic lesio

164 5% CI, 3.0-3.4; P<0.001) among patients with ACHD compared with matched controls.

165 of an international cohort of patients with ACHD enrolled in APPROACH IS-II between February 10, 201

166 register-based cohort study of patients with ACHD surviving to 18 years of age, the risk of mortality

167 All patients with ACHD treated with SGLT2i in 4 European ACHD centers were

168 k decline in the mortality for patients with ACHD was seen for those born after 1975.

169 50 years of follow-up, >75% of patients with ACHD were still alive.

170 In total, 174 patients with ACHD were treated with SGLT2i from April 2016 to July 20

171 Clinically stable patients with ACHD who routinely visited the outpatient clinic between

172 or the routine surveillance of patients with ACHD.

173 and potentially beneficial in patients with ACHD.

174 tential benefits of SGLT2i for patients with ACHD.

175 e monitoring and management of patients with ACHD.

176 ociated complications in older patients with ACHD.

177 Within ACHD subgroups, peak VO2 gradually declined from aortic

178 igher compared with matched controls without ACHD.

179 ower-complexity ACHD and individuals without ACHD for comparison among >500 000 British adults in the

180 s, in contrast to 13% in individuals without ACHD with >=5 risk factors.

181 porter 2 inhibitors (SGLT2i) in a real-world ACHD population.